Nature Medicine
- 12, 1125 - 1126 (2006)
doi:10.1038/nm1006-1125
Targeted cancer treatment: resisting arrest
Dominik Wodarz
Dominik Wodarz is in the Department of Ecology and Evolutionary Biology, 321 Steinhaus Hall, University of California, Irvine, California 92697, USA. dwodarz@uci.edu
kanjiMany individuals with chronic myeloid leukemia have benefited from the drug imatinib (Gleevec)—but if they are taken off the drug, relapse occurs. Two mathematical models to explain this phenomenon, one described in this issue, have come to different conclusions (1181–1184).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
